Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Keith Thomas Flaherty, M.D.

Co-Author

This page shows the publications co-authored by Keith Flaherty and Eliezer Van Allen.
Connection Strength

0.349
  1. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021 06; 27(6):985-992.
    View in: PubMed
    Score: 0.060
  2. Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2020 Jul; 26(7):1147.
    View in: PubMed
    Score: 0.057
  3. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019 12; 25(12):1916-1927.
    View in: PubMed
    Score: 0.055
  4. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
    View in: PubMed
    Score: 0.051
  5. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
    View in: PubMed
    Score: 0.047
  6. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016 Apr 08; 352(6282):189-96.
    View in: PubMed
    Score: 0.043
  7. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.